Palisade Bio (PALI) Liabilities from Discontinued Operations (2020 - 2021)
Palisade Bio's (PALI) quarterly Liabilities from Discontinued Operations came in at 219757.0 in Q1 2021, down 6.22% on a QoQ basis from 234344.0 in Q4 2020.
Palisade Bio (PALI) Liabilities from Discontinued Operations (2020 - 2021) Analysis & Trends
Palisade Bio (PALI) has 2 years of Liabilities from Discontinued Operations data on file, last reported at 219757.0 in Q1 2021.
- On a quarterly basis, Liabilities from Discontinued Operations changed N/A year-over-year to 219757.0 in Q1 2021; TTM through Mar 2021 was 219757.0, a N/A change from a year earlier, with the FY2020 full-year figure at 234344.0, changed N/A from the prior year.
- Liabilities from Discontinued Operations for Q1 2021 stood at 219757.0, down from 234344.0 in the prior quarter.
- Over the last five years, Liabilities from Discontinued Operations for PALI reached as high as 325812.0 in Q3 2020 and fell as low as 219757.0 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Palisade Bio | 985.76 | -132.63 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 219,757.00 |
| Mar 31, 2021 | 219,757.00 |
| Dec 31, 2020 | 234,344.00 |
| Dec 31, 2020 | 234,344.00 |
| Sep 30, 2020 | 325,812.00 |
| Sep 30, 2020 | 325,812.00 |